CD274 and non-small cell lung carcinoma: MK-1084 is being tested for KRAS G12C mutations as monotherapy in pretreated patients with advanced solid tumors (arm 1) and in combination with pembrolizumab in previously untreated metastatic NSCLC with PD-L1 TPS≥1% in an ongoing, phase 1, global, dose-escalation trial (arm 2) (23).